Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue (2018 - 2022)

Ani Pharmaceuticals' Current Deferred Revenue history spans 8 years, with the latest figure at $116000.0 for Q1 2022.

  • On a quarterly basis, Current Deferred Revenue rose 16.0% to $116000.0 in Q1 2022 year-over-year; TTM through Mar 2022 was $116000.0, a 16.0% increase, with the full-year FY2021 number at $87000.0, down 13.0% from a year prior.
  • Current Deferred Revenue hit $116000.0 in Q1 2022 for Ani Pharmaceuticals, up from $87000.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for ANIP hit a ceiling of $735000.0 in Q3 2018 and a floor of $87000.0 in Q4 2021.
  • Historically, Current Deferred Revenue has averaged $318800.0 across 5 years, with a median of $125000.0 in 2020.
  • Biggest five-year swings in Current Deferred Revenue: crashed 80.0% in 2020 and later rose 16.0% in 2022.
  • Tracing ANIP's Current Deferred Revenue over 5 years: stood at $711000.0 in 2018, then decreased by 29.68% to $500000.0 in 2019, then crashed by 80.0% to $100000.0 in 2020, then dropped by 13.0% to $87000.0 in 2021, then soared by 33.33% to $116000.0 in 2022.
  • Business Quant data shows Current Deferred Revenue for ANIP at $116000.0 in Q1 2022, $87000.0 in Q4 2021, and $100000.0 in Q3 2021.